866-997-4948(US-Canada Toll Free)

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 55 Pages

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Matrix Metalloproteinase 9-Pipeline Review, H2 2017'; Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) pipeline Target constitutes close to 18 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)-Matrix metallopeptidase 9 (MMP-9) is a matrixin that belong to the zinc-metalloproteinases family. It plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration and bone osteoclastic resorption. MMP9 along with elastase, appears to be a regulatory factor in neutrophil migration across the basement membrane. MMP9 may play an important role in wound repair, angiogenesis and neovascularization.

The report 'Matrix Metalloproteinase 9-Pipeline Review, H2 2017' outlays comprehensive information on the Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Cardiovascular, Gastrointestinal, Dermatology, Genetic Disorders, Immunology, Musculoskeletal Disorders, Respiratory, Infectious Disease, Male Health, Ophthalmology and Undisclosed which include indications Myocardial Infarction, Neuropathic Pain, Congestive Heart Failure (Heart Failure), Crohn's Disease (Regional Enteritis), Hypertension, Marfan Syndrome, Wounds, Acute Pain, Adenocarcinoma Of The Gastroesophageal Junction, Aneurysm, Cancer Pain, Chronic Obstructive Pulmonary Disease (COPD), Chronic Pain, Cystic Fibrosis, Dupuytren Contracture, Epilepsy, Fibrosis, Gastric Cancer, Herpes Labialis (Oral Herpes), Keratoconjunctivitis sicca (Dry Eye), Liver Fibrosis, Lung Adenocarcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Opium (Opioid) Addiction, Osteoarthritis Pain, Pancreatic Islet Transplant Rejection, Peyronies Disease, Pulmonary Fibrosis, Rheumatoid Arthritis, Solid Tumor, Squamous Non-Small Cell Lung Carcinoma, Stroke, Traumatic Brain Injury and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
- The report reviews Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics and enlists all their major and minor projects
- The report assesses Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)-Overview 7
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)-Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 12
Products under Development by Universities/Institutes 16
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)-Therapeutics Assessment 18
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)-Companies Involved in Therapeutics Development 23
EA Pharma Co Ltd 23
Gilead Sciences Inc 23
Iproteos SL 24
Shulov Innovative Science Ltd 24
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)-Drug Profiles 26
andecaliximab-Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
AQU-005-Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
AQU-010-Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
AQU-118-Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CALY-001-Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
IPRO-003-Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Monoclonal Antibodies to Inhibit MMP-2 and MMP-9 for Crohn's Disease-Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
ND-336-Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ND-478-Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Protearin-Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Peyronies Disease, Dupuytren Contracture and Pancreatic Islet Transplant Rejection-Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Recombinant Protein to Target MMP-9 for Wounds-Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
SI-1004-Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
SI-1005-Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecule to Inhibit Matrix Metalloproteinase 9 for Oncology-Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma-Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecules to Inhibit MMP for Myocardial Infarction-Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ZEP-3-Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)-Dormant Products 46
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)-Discontinued Products 49
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)-Product Development Milestones 50
Featured News & Press Releases 50
Nov 02, 2016: Abzena Provides Update on GS-5745 50
Sep 21, 2016: Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis 50
Jun 28, 2016: NeuroMax Announces Start Phase 1 Clinical Trial of AQU-005 for the Treatment of Neuropathic Pain 50
May 13, 2015: Abzena provides an update on the clinical development of one of the humanized antibodies created using its Composite Human Antibody technology 51
Dec 26, 2011: New Antibodies Treat Autoimmune Disease in Mice 51
Oct 08, 2011: Researchers from Notre Dame university create breakthrough in neurological diseases 52
Oct 06, 2011: Notre Dame researchers make neurological disease breakthrough 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indications, H2 2017 10
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 15
Number of Products under Investigation by Universities/Institutes, H2 2017 16
Products under Investigation by Universities/Institutes, H2 2017 17
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Stage and Route of Administration, H2 2017 20
Number of Products by Stage and Molecule Type, H2 2017 22
Pipeline by EA Pharma Co Ltd, H2 2017 23
Pipeline by Gilead Sciences Inc, H2 2017 24
Pipeline by Iproteos SL, H2 2017 24
Pipeline by Shulov Innovative Science Ltd, H2 2017 25
Dormant Products, H2 2017 46
Dormant Products, H2 2017 (Contd..1), H2 2017 47
Dormant Products, H2 2017 (Contd..2), H2 2017 48
Discontinued Products, H2 2017 49

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Routes of Administration, H2 2017 19
Number of Products by Stage and Routes of Administration, H2 2017 19
Number of Products by Molecule Types, H2 2017 21
Number of Products by Stage and Molecule Types, H2 2017 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *